Want to see JP:4595 full AI Analyst Report?
Mizuho Medy Co., Ltd. (4595) AI Stock Analysis
Mizuho Medy Co., Ltd.
(TSE/TYO:4595)
Mizuho Medy's overall score of 79.1 reflects its strong financial health and attractive valuation, tempered by recent technical weakness and declining cash flows. The company's debt-free balance sheet and robust profitability are key strengths, while the high dividend yield and low P/E offer compelling value. However, the stock's price is currently below key moving averages, signaling near-term bearish sentiment, and cash flow generation has weakened, warranting monitoring.
Mizuho Medy Co., Ltd. (4595) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 32.34B
- Dividend Yield
- 5.89%
- Average Volume (3M)
- 78.88K
- Price to Earnings (P/E)
- 10.0
- Beta (1Y)
- 0.40
- Revenue Growth
- 0.75%
- EPS Growth
- -2.33%
- Country
- Japan
- Employees
- 193
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Mizuho Medy Co., Ltd. Business Overview & Revenue Model
Company Description
Established in 1977 and headquartered in Tosu, Japan, Mizuho Medy Co.,Ltd. specializes in the research, development, production, and distribution of in-vitro diagnostic solutions, complemented by scientific and technical information services. While i...
How the Company Makes Money
null
Mizuho Medy Co., Ltd. Financial Statement Overview
Summary
Strong profitability (gross margin 69.1%, net margin 30.4%) and a debt-free balance sheet, but cash flow has declined significantly, raising concerns about sustainability.
Income Statement
85Very PositiveBalance Sheet
95Very PositiveCash Flow
70Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.82B | 11.26B | 11.43B | 10.99B | 17.58B | 12.89B |
| Gross Profit | 7.40B | 7.78B | 8.04B | 8.03B | 14.05B | 9.61B |
| EBITDA | 4.44B | 4.91B | 5.10B | 5.40B | 11.26B | 6.87B |
| Net Income | 3.23B | 3.42B | 3.77B | 3.77B | 7.84B | 4.82B |
Balance Sheet | ||||||
| Total Assets | 20.99B | 22.38B | 20.73B | 18.95B | 19.10B | 12.19B |
| Cash, Cash Equivalents and Short-Term Investments | 13.06B | 10.82B | 11.25B | 10.13B | 8.70B | 4.33B |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.43B | 3.69B | 3.37B | 3.27B | 4.82B | 4.16B |
| Stockholders Equity | 18.55B | 18.68B | 17.35B | 15.68B | 14.28B | 8.03B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 1.70B | 3.05B | 3.73B | 5.99B | 5.44B |
| Operating Cash Flow | 0 | 1.96B | 3.35B | 3.99B | 6.17B | 5.60B |
| Investing Cash Flow | 0 | -7.28B | -307.00M | -270.45M | -1.55B | -159.74M |
| Financing Cash Flow | 0 | -2.08B | -2.09B | -2.38B | -1.57B | -1.16B |
Mizuho Medy Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4595, the sentiment is Negative. The current price of 1698.00 is below the 20-day moving average (MA) of 1717.95, below the 50-day MA of 1720.98, and below the 200-day MA of 1717.41, indicating a bearish trend. The MACD of -2.53 indicates Positive momentum. The RSI at 42.69 is Neutral, neither overbought nor oversold. The STOCH value of 15.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4595.
Mizuho Medy Co., Ltd. Peers Comparison
Overall Rating
- JP:459579.1Outperform
JP:453468Neutral
JP:488666Neutral
JP:455460Neutral
JP:489250Neutral
JP:453946.5Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4595 | 79Outperform | JPY 32.59B | 10.02 | ― | 5.89% | 0.75% | -2.33% |
| JP:4534 | 68Neutral | JPY 111.78B | 12.59 | 6.64% | 2.53% | 14.72% | 52.55% |
| JP:4886 | 66Neutral | JPY 52.85B | 11.79 | ― | 3.32% | ― | -7.20% |
| JP:4554 | 60Neutral | JPY 48.76B | 15.88 | 6.04% | 2.13% | 20.36% | -5.53% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4892 | 50Neutral | JPY 5.64B | -6.65 | ― | ― | 364.72% | 18.43% |
| JP:4539 | 47Neutral | JPY 5.47B | -11.34 | ― | 3.35% | 0.31% | -194.72% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4595 | Mizuho Medy Co., Ltd. | 1698.00 | 146.17 | 9.42% | |
| JP:4554 | Fuji Pharma Co., Ltd. | 1889.00 | 320.64 | 20.44% | |
| JP:4534 | Mochida Pharmaceutical Co., Ltd. | 3265.00 | 292.28 | 9.83% | |
| JP:4539 | Nippon Chemiphar Co., Ltd. | 1494.00 | 9.29 | 0.63% | |
| JP:4886 | ASKA Pharmaceutical Holdings Co., Ltd. | 1957.00 | -96.16 | -4.68% | |
| JP:4892 | Cyfuse Biomedical K.K. | 541.00 | -44.00 | -7.52% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 06, 2026